O
Olema Pharmaceuticals, Inc. (OLMA)
NMS – Real Time Price. Currency in USD
11.39
-0.04 (-0.35%)
At close: Jun 26, 2026, 4:00 PM EDT
11.17
-0.22 (-1.93%)
After-hours: Jun 26, 2026, 5:08 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
11.39
-0.04 (-0.35%)
At close: Jun 26, 2026, 4:00 PM EDT
11.17
-0.22 (-1.93%)
After-hours: Jun 26, 2026, 5:08 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Company's cash reserves $52.5M significantly exceed its total debt $4.0M, ensuring strong financial flexibility
Total current assets $513.2M exceed Total current liabilities $47.2M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$46.0M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 10.88 | 6.05 | 10 | |
| Quick ratio | 10.88 | 5.63 | 10 | |
| Debt to Equity | 0.01 | 0.30 | 10 | |
| Debt to Assets | 0.01 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -2M | -377K | -393K | -490K | -481K |
| Operating Income | -107M | -105M | -142M | -179M | -202M |
| Net Income | -105M | -97M | -129M | -162M | -185M |
| EBITDA | -105M | -105M | -142M | -178M | -201M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | -8.28 | 1.0 |
| Next quarter | N/A | -15.61 | 1.0 |
| Current year | N/A | -18.74 | 1.0 |
| Next year | 1356.58 | -10.28 | 5.5 |
| Weighted average score | 2.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -15.25 | -3.99 | -19.98 | 3.3 |
| Y/Y | 999 | -74.69 | -44.43 | -4.56 | 3.3 |
| 3y average | 999 | -17.2 | 10.18 | -22.24 | 4.8 |
| 5y average | 999 | -64.07 | 5.57 | -57.35 | 4.3 |
| Weighted average score | 3.9 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |